Prospective, Open-Label, Non-Comparative, Study to Assess the Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study evaluates the long term safety and efficacy of use of the Butterfly Medical's prostatic retraction device in Benign Prostatic Hyperplasia (BPH) Patients. The study follows patients implanted with the Butterfly device for up to 5 year after implantation. The evaluations include recording of safety events and BPH related symptoms by Uroflowmetry tests, residual urine and International Prostate Symptom Score (IPSS) questionnaires. The study also assesses the sexual quality of life after implantation of the Butterfly device.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:

• Completed 12 months follow up under study BM-011-IL. A subject that missed one or more visits during BM-011-IL will be included, as long as the subject has collected data at 12 months follow up visit.

• Provide signed informed consent to the continuation study and be willing and able to perform follow up visits and activities as described in the study protocol.

Locations
Other Locations
Israel
Rabin Medical Center
RECRUITING
Petah Tikva
Ziv Medical Center
RECRUITING
Safed
Contact Information
Primary
Vardit Segal, Ph.D
vardit@butterfly-medical.com
+972524579178
Backup
Idan Geva
Idan.geva@butterfly-medical.com
+972504043838
Time Frame
Start Date: 2021-02-10
Estimated Completion Date: 2027-02-01
Participants
Target number of participants: 60
Treatments
Experimental: Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation
Continuation study for Study BM-011-IL
Related Therapeutic Areas
Sponsors
Leads: Butterfly Medical Ltd.

This content was sourced from clinicaltrials.gov